- 4 October 2018
2:30 pm - 3:30 pm
Thursday 4 October 2018, 2.30 pm – 3.30 pm
Auditorium, Level 6, Bancroft, QIMR Berghofer
My role in discovering p53: the guardian of our genes and our protector against cancer
40 years ago, at the tender age of 25, while writing up my PhD and doing my first research project I discovered a new protein, now called p53. I have worked on this protein ever since. Ten years after its discovery, after many false starts, it became clear that mutations in the gene that makes p53 are the most common genetic change in human cancer. It is now the most researched gene in the world but a full understanding of how it protects us from cancer and how p53 can be used to save lives remain my goal. The 40 year journey has been amazing and I look forward to sharing it with you.
Professor Sir David Lane
Sir David is the Chief Scientist of A*STAR, where his main role is to advise and engage in scientific development across the Biomedical Research Council (BMRC) and the Science and Engineering Research Council (SERC) at the strategic level. He also runs a research lab primarily focusing on research on p53 using both mammalian and zebrafish systems.
Sir David completed undergraduate and postgraduate degrees at University College London where he studied auto-immunity. He did his postdoctoral training at the Imperial Cancer Research Fund in London (where he discovered p53 as a T antigen binding protein) and then at the Cold Spring Harbor Labs in New York. On his return to UK, he set up his independent research lab at Imperial College London and at the ICRF Clare Hall labs before moving to the University of Dundee.
Sir David has published more than 400 research articles in international peer reviewed journals many of which have been very highly citied and has co-authored a successful practical guide to the use of immunochemical methods called “Antibodies” with Ed Harlow, selling more than 40,000 copies. He is the founder of Cyclacel, a NASDAQ listed company with three drugs in Clinical trial. Sir David established the Experimental Therapeutics Centre at A*Star in 2007. He was formerly the Chief Scientist at Cancer Research UK and for three years the Scientific Director of the Ludwig Institute. He has been recognized for his work by many international awards including the Paul Ehrlich Prize, the Brucbacher Prize, the Buchanan Medal of the Royal Society and the Royal Medal of the Royal Society of Edinburgh. Last year he received the Presidents Science and Technology Medal in Singapore for his contribution to the development of Science in the Republic.
Cocktail function to follow
Register your attendance below by Friday 28 September 2018